KOL Views: Reassessing the outlook for anti-PD(L)1 drugs – individually and collectively – in NSCLC in the wake of ESMO

Opdivo (nivolumab) was the market leader in non-small-cell lung cancer (NSCLC) until the door was thrown open for competing anti-PD-(L)1 agents when it unexpectedly failed a front-line Phase III trial in August. New data from this year’s ESMO congress suggest the Bristol-Myers Squibb’s pain is likely to be Merck & Co.’s – and to a lesser extent Roche’s – gain. (See ESMO – Five key questions raised by new PD-1 inhibitor datasets.)

To provide FirstWord readers with a look at how the updated results impact the battle for control of the NSCLC market, we are hosting an expert call with a leading key opinion leader on Wednesday (October 12).

Key topics to be discussed include, among other things… feedback on the Opdivo, Keytruda (pembrolizumab) and Tecentriq (atezolizumab) datasets; how and when physicians are likely to use anti-PD-(L)1 monotherapy, chemo-containing combinations and immuno-oncology doublets; how treatment landscape is likely to change over the next few years; and where might other fast-followers like AstraZeneca and Pfizer fit in.

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues related to the evolving NSCLC treatment paradigm.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.